Rocaglamide Liposomes, Formulation KHE9A

Mfr.No.	DLL-0019, DLL-0019-1A-5MG, DLL-0019-1A-10MG, DLL-0019-1A-25MG
Alternative Names	Roc-A
Average Size	70-120 nm
Hydration Solution	292 mM sucrose, 0.5% DPBS (1X)
External Solution	KHE9A
Signaling pathway	NFkappaB pathway, heat shock response
Description	PEGylated liposomes containing Rocaglamide (Roc-A). Rocaglamide is a potent inhibitor of NF-kappaB activation in T-cells. Rocaglamide is a potent and selective HSF1 activation inhibitor (IC50 ~50 nM). Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also exhibits anti-leukemia activity. Rocaglamide is insoluble in aqueous media. This product is a pre-formulated liposomal version of Rocaglamide which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
Concentration	4.0 mg/mL (+- ~5%)
Concentration Total Lipid	60 mM
Cas Number	84573-16-0
Types of Liposomes	Drug Loaded Liposomes
Target	NFkappaB, HSF1, eIF4A

Have you used this product?

Combination SKU	Supplier No.	Volume	Your price
BHB19400012-1	DLL-0019-1A-5MG	5 mg	$1295	Add to Cart
BHB19400012-2	DLL-0019-1A-10MG	10 mg	$1995	Add to Cart
BHB19400012-3	DLL-0019-1A-25MG	25 mg	$3295	Add to Cart